NICE Recommends Novartis’ Piqray and Gilead’s Trodelvy for Advanced Breast Cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Piqray (alpelisib) for National Health Service (NHS) use in combination with the hormonal therapy fulvestrant for treating certain breast cancer patients.

Specifically, NICE endorsed the combination treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative and PIK3CA-mutated locally advanced or metastatic breast cancer that has progressed following prior treatment.

NICE said the treatment combination meets the agency’s criteria for a life-extending treatment at the end of life and offers a longer life compared with chemotherapy.

The recommended dose for Piqray is 300 mg once daily. The UK list price for this drug is more than $4,800 per 56-pack of 150 mg film-coated tablets. The negotiated price for NHS use was not disclosed.

NICE has also recommended Gilead Sciences’ Trodelvy (sacituzumab govitecan) for treating locally advanced or metastatic triple-negative breast cancer which can’t be removed surgically and that follows at least two lines of systemic therapy.

The recommended dose of Trodelvy is 10 mg/kg administered by intravenous infusion once weekly on days one and eight of 21-day treatment cycles. The UK list price for the treatment is more than $930 per 180 mg vial. The negotiated NHS price was not disclosed.